Dendritic cell-based vaccines: Shining the spotlight on signal 3

Dendritic cell (DC)-based anticancer vaccines have yielded disappointing results in a multitude of clinical trials. New data suggest that the clinical efficacy of DC-based vaccines may be dependent on the paracrine production of interleukin-12 in the course of antigen presentation and the consequent...

Descripción completa

Detalles Bibliográficos
Autores principales: Linette, Gerald P, Carreno, Beatriz M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3881596/
https://www.ncbi.nlm.nih.gov/pubmed/24404428
http://dx.doi.org/10.4161/onci.26512
Descripción
Sumario:Dendritic cell (DC)-based anticancer vaccines have yielded disappointing results in a multitude of clinical trials. New data suggest that the clinical efficacy of DC-based vaccines may be dependent on the paracrine production of interleukin-12 in the course of antigen presentation and the consequent development of therapeutic Type 1 CD8(+) T-cell immunity.

Ejemplares similares